Patents Examined by Gailene Gabel
  • Patent number: 11371984
    Abstract: An apparatus for analyzing particles in a solution includes a unit configured to place a flow cell having a flow path for flowing a sample solution containing the particles; a unit configured to illuminate the sample solution flowing through the flow path of the flow cell; a photodetector that detects a scattered light and/or fluorescence generated from the particles in the sample solution; and a unit configured to analyze the particles based on their signal intensities detected by the photodetector, wherein the flow cell has the flow path formed in a substrate, a reflection plane is formed on the side surface of the flow path, the reflection plane leads the lights generated in the flow path of the flow cell and advancing in the substrate in-plane direction to a specified region of the surface of the flow cell, and the photodetector detects the light exiting from the specified region to the outside.
    Type: Grant
    Filed: April 6, 2019
    Date of Patent: June 28, 2022
    Assignee: ON-CHIP BIOTECHNOLOGIES CO., LTD.
    Inventor: Kazuo Takeda
  • Patent number: 11360092
    Abstract: The current disclosure provides methods for detecting and analyzing K17 expression in a bladder sample obtained from a subject. The current disclosure also pertains to methods and kits for identifying a mammalian subject with bladder cancer by detecting the expression of K17 in a sample. The present methods include both cell-based and cell-free methods for determining the level of keratin 17 in a sample obtained from the bladder of a subject.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: June 14, 2022
    Assignees: The Research Foundation for The State University of New York, KDx Diagnostics, Inc.
    Inventors: Kenneth R. Shroyer, Luisa F. Escobar-Hoyos, Nam Kim
  • Patent number: 11360087
    Abstract: Use of (i) an anti-CD3 antibody, (ii) an anti-CD56 antibody, (iii) an anti-CD14 antibody, (iv) an anti-CD38 antibody, (v) an anti-CD45 antibody, (vi) an anti-CD90 antibody, (vii) an anti-CD135 antibody, (viii) an anti-CD10 antibody, (ix) an anti-CD11c antibody, (x) an anti-CD19 antibody, (xi) an anti-CD34 antibody, (xii) an anti-CD45RA antibody, (xiii) an anti-CD7 antibody, (xiv) an anti-CD71 antibody, (xv) an anti-CD41/CD61 complex antibody or an anti-CD41 antibody and/or an anti-CD61 antibody (xvi) an anti-CD33 antibody and/or an anti-CD66b antibody, for identifying hematopoietic cell subtypes in an isolated sample, determining the relative frequency of hematopoietic cell subtypes in an isolated sample and/or quantifying the number of cells within hematopoietic cell subtypes in an isolated sample, wherein each of (i) to (xvi) is labelled with a different fluorochrome, wherein when (xvi) is an anti-CD33 antibody and an anti-CD66b antibody, the anti-CD33 antibody and anti-CD66b are labelled with the same fluo
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: June 14, 2022
    Assignees: Ospedale San Raffaele S.R.L., Fondazione Telethon
    Inventors: Luca Basso-Ricci, Luca Biasco, Alessandro Aiuti
  • Patent number: 11346838
    Abstract: The present disclosure relates to a bioparticle measuring method including forming on a solid phase a complex of a sample containing a bioparticle sampled from a specimen, a capturer containing a tag which binds to the solid phase and capable of binding to the bioparticle, and a detector capable of binding to the bioparticle and containing a labeled substance. A part or the whole of the complex may be dissociated from the solid phase to prepare a measurement sample containing a part or the whole of the complex not fixed on the solid phase, and signals from the measurement sample may be detected by a particle analyzer.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: May 31, 2022
    Assignee: SYSMEX CORPORATION
    Inventors: Kazuya Matsumoto, Takuya Iino, Keiko Yoshikawa
  • Patent number: 11340225
    Abstract: The present disclosure provides methods of assaying for antibody-dependent cell-mediated phagocytosis (ADCP). In some embodiments, the methods include monomerizing and labeling a protein, contacting the protein with a protein-specific antibody to form an antibody-protein complex, contacting the antibody-protein complex with a phagocytic cell to permit phagocytosis, and assessing the amount of internalized fluorescence.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: May 24, 2022
    Assignee: Biogen International Neuroscience GmbH
    Inventors: Carl Co, Allyson Masci, Svetlana Bergelson
  • Patent number: 11320439
    Abstract: The present disclosure is in the field of in vitro diagnostics and relates to an easily automatable binding assay for establishing a heparin-induced thrombocytopenia, which binding assay uses Fc?RIIa protein-coated particles.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: May 3, 2022
    Assignee: Siemens Healthcare Diagnostics Products GmbH
    Inventors: Harald Althaus, Herbert Schwarz, Norbert Zander
  • Patent number: 11313855
    Abstract: The present invention relates to methods and compositions to remove or reduce biotin interference from certain assays.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: April 26, 2022
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventor: Tie Wei
  • Patent number: 11287429
    Abstract: Kits containing a multiplexed chemiluminescent detection system and microfluidics devices and methods for detecting the presence and/or concentration of biotin and at least one target analyte in a sample are disclosed. The kits, microfluidics devices, and methods utilize singlet oxygen-activatable chemiluminescent compounds in combination with two or more fluorescent molecules that emit light at different wavelengths.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: March 29, 2022
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventor: Tie Wei
  • Patent number: 11287427
    Abstract: In spite of significant efforts to identify ?-cell-specific markers for ?-cell imaging and purification, progress has been limited. Herein is disclosed a novel biomarker of human pancreatic ?-cells, CD39L3 (also known as ectonucleoside triphosphate diphosphohydrolase-3 (NTPDase3)). Disclosed are compositions and methods for purifying and imaging ?-cell using anti-CD39L3 antibodies.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: March 29, 2022
    Assignees: VANDERBILT UNIVERSITY, THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Alvin C. Powers, Marcela Brissova, Chunhua Dai, Neil Phillips, Diane Saunders
  • Patent number: 11280783
    Abstract: This disclosure relates to devices, assays, and methods related to airway inflammation caused by polymorphonuclear neutrophils (PMNs). In certain embodiments, the disclosure relates to a model device that emulates the changes in airway cell physiology due to transmigration of PMNs from blood to the cells at the air-liquid interface. In certain embodiments, the airway cells are supported on a collagen layer wherein the collagen layer is further supported by a porous polymer from which PMNs can migrate. In certain embodiments, the disclosure contemplates adding bacteria, fungi and/or viruses to the device to emulate disease states. In certain embodiments, the disclosure relates to the use of the model system to test compounds to identify drug candidates and diagnose subjects with airway-related diseases and conditions.
    Type: Grant
    Filed: April 29, 2020
    Date of Patent: March 22, 2022
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventor: Rabindra M. Tirouvanziam
  • Patent number: 11280792
    Abstract: The object of the present invention is to provide an evaluation method capable of accurately determining a metastasis of cancer, the stage of cancer progression, or the malignancy of cancer.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: March 22, 2022
    Assignees: ON-CHIP BIOTECHNOLOGIES CO., LTD., SHIZUOKA PREFECTURE
    Inventors: Kazuo Takeda, Namiko Yamashita, Yuu Fujimura, Kaori Nishio, Yasuhiro Koh, Masaru Watanabe, Fumiaki Koizumi, Yuri Uehara
  • Patent number: 11268951
    Abstract: The present invention provides compositions, kits, and methods for the detection of host cell proteins (HCPs) in biological samples. In some embodiments, the present invention utilizes immunization of aves hosts with proteins derived from non-aves host cells to produce aves antibodies specific for non-aves HCPs.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: March 8, 2022
    Assignee: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
    Inventor: Olaf Stamm
  • Patent number: 11262366
    Abstract: Hemoglobin, its variants, and glycated forms of each are determined individually in a multiplex assay that permits correction of the measured level of HbA1c to account for glycated variants and other factors related to the inclusion of the variants in the sample. New antibodies that are particularly well adapted to the multiplex assay are also provided.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: March 1, 2022
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Roger Walker, Benedicte Jardin
  • Patent number: 11255854
    Abstract: The present invention provides methods, devices, compositions (e.g., capture complexes), and kits useful for enhancing the detection of antibodies in a test sample. The methods, devices, and compositions utilize detectable Fc-binding molecules such as Protein A, Protein G, and/or an Fc-specific antibody to amplify the signal of a detected antibody in immunoassays, such as lateral flow assays.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: February 22, 2022
    Assignee: Zoetis Services LLC
    Inventors: Rajesh K. Mehra, Kenneth P. Aron, Dennis M. Bleile, Jeremy Walker, Cristina Cuesico
  • Patent number: 11255850
    Abstract: A method includes attaching two or more beads to each unit of one or more units of a chemical component in a sample, to form, for each unit of the chemical component, a multi-bead complex including two or more beads and the unit of the chemical component; placing the sample on a surface of an image sensor; at the image sensor, receiving light originating at a light source, the received light including light reflected by, refracted by, or transmitted through the beads of the multi-bead complexes; at the image sensor, capturing one or more images of the sample from the received light; and identifying, in at least one of the images of the sample, separate multi-bead complexes, the identifying of the separate multi-bead complexes including associating the two or more beads of each of the multi-bead complexes based on proximity to one another.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: February 22, 2022
    Inventor: Alan Marc Fine
  • Patent number: 11249077
    Abstract: The present disclosure relates to a method for labeling particles with magnetic particles and an apparatus for labeling particles with magnetic particles.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: February 15, 2022
    Assignee: ARKRAY, Inc.
    Inventors: Hiroshi Ito, Masahiro Kozuka, Takahide Inouchi, Shigeru Kitamura
  • Patent number: 11231422
    Abstract: Plasma levels of different sub-populations of microvesicles (endothelial, leukocyte, platelet and hepatocyte) were measured by flow cytometry or ELISA/filtration on blood samples from 125 patients with cirrhosis, for which 36 of them were diagnosed with HCC at inclusion. The inventors show that the levels of microvesicles of endothelial origin (CD62E+) could predict the occurrence of HCC in patients with cirrhosis. Therefore the present invention relates to a method for determining whether a patient suffering from cirrhosis is at risk of having or developing hepatocellular carcinoma comprising determining the level of endothelial-derived microvesicles (e.g. by flow cytometry) in a blood sample obtained from the patient.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: January 25, 2022
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paris Descartes, Assistance Publique Hôpitaux de Paris (APHP), UniversitéParis Diderot—Paris 7
    Inventors: Pierre-Emmanuel Rautou, Chantal Boulanger-Robert
  • Patent number: 11226332
    Abstract: The present invention relates an in vitro method for detecting class II restricted CD4+ T cells in a sample. Herein a sample is contacted with an isolated complex of an MHC class II molecule and a peptide. This peptide comprises an MHC class II restricted T cell epitope of an antigenic protein and immediately adjacent thereof, or separated by a linker of at most 7 amino acids a sequence with a [CST]-xx-C or C-xx-[CST] motif. CD4+ T cells are detected by measuring the binding of the complex with cells in the sample, wherein the binding of the complex to a cell is indicative for the presence of CD4+ T cells in the sample. The present invention further relates to an isolated complex of an MHC Class II molecule and a peptide comprising an MHC class II restricted T cell epitope of an antigenic protein and immediately adjacent thereof, or separated by a linker of at most 7 amino acids a sequence with a [CST]-xx-C or C-xx-[CST] motif.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: January 18, 2022
    Assignee: IMCYSE SA
    Inventors: Jean-Marie Saint-Remy, Vincent Carlier, Luc Vander Elst
  • Patent number: 11199541
    Abstract: According to some aspects, a method for analyzing a cell is provided. The method includes trapping the cell by binding a first molecule to the cell. The method further includes binding a second molecule to the cell. The second molecule includes a binding portion capable of specific binding to a cell-surface molecule of the cell. The second molecule further includes an identifying portion, a labeling portion coupled to the identifying portion, and a stimulus-degradable linker between the binding portion and the identification portion. The method further includes detaching the identifying portion from the binding portion by stimulating the stimulus-degradable linker where the detached identifying portion is coupled to the labeling portion. The method further includes binding the detached identifying portion through specific binding to an identifying portion recognizing molecule and detecting the labeling portion.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: December 14, 2021
    Assignee: Sony Corporation
    Inventors: Masahiro Matsumoto, Masataka Shinoda, Yuuki Watanabe
  • Patent number: 11175282
    Abstract: The present invention provides a method to quantitatively measure the response of a patient to an immune-modulator drug that will aid clinicians in the determination of the optimal combination/posology of immunosuppressant/immune-modulator drugs. In addition, this method will open the possibility for clinicians to make the necessary adjustments in immunosuppressive therapy, as a way to avoid organ rejection to actually take place. Furthermore, this method will significantly reduce side effects of immunosuppressant drugs, optimizing therapeutic scheme and dosages, enabling the determination of the most effective immunosuppression regimen at the lower dosages for each patient individually and monitoring of treatment efficiency along time, thus opening the door to treatment personalization.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: November 16, 2021
    Assignee: BIOHOPE SCIENTFIC SOLUTIONS FOR HUMAN HEALTH S.L.
    Inventors: Javier Dotor De Las Herrerías, Marianna Di Scala, Verónica Sánchez, Isabel Portero Sánchez